The coagulation defect ICD 10 codes fall primarily under categories D66 through D69, covering everything from hemophilia A and B to von Willebrand disease and acquired clotting disorders. If you’re a coder trying to assign the right diagnosis, a clinician working up a bleeding patient, or a student trying to connect the dots between pathophysiology and billing — this guide maps out the specific codes, the clinical picture behind each one, and how these disorders are actually diagnosed and managed in practice.
The most commonly used code in this group is D68.9 — Coagulation defect, unspecified. It’s a catch-all that gets used (sometimes overused) when a patient has abnormal coagulation labs but the specific defect hasn’t been pinned down yet. However, accurate coding matters — it drives reimbursement, tracks disease prevalence, and increasingly influences clinical decision support tools. Let’s break down the specifics.
ICD 10 Codes for Coagulation Defects: Complete Reference Table
| ICD 10 Code | Condition | Key Clinical Feature |
|---|---|---|
| D66 | Hereditary factor VIII deficiency (Hemophilia A) | Prolonged aPTT, joint/muscle bleeding |
| D67 | Hereditary factor IX deficiency (Hemophilia B) | Prolonged aPTT, clinically similar to hemophilia A |
| D68.0 | Von Willebrand disease | Mucocutaneous bleeding, prolonged bleeding time |
| D68.1 | Hereditary factor XI deficiency (Hemophilia C) | Variable bleeding, common in Ashkenazi Jewish population |
| D68.2 | Hereditary deficiency of other clotting factors (II, V, VII, X, XII, XIII) | Varies by factor; some are incidental lab findings |
| D68.31 | Hemorrhagic disorder due to intrinsic circulating anticoagulants | Acquired factor VIII inhibitor, lupus anticoagulant |
| D68.32 | Hemorrhagic disorder due to extrinsic circulating anticoagulants | Drug-related (warfarin, heparin, DOACs) |
| D68.4 | Acquired coagulation factor deficiency | Liver disease, vitamin K deficiency, DIC |
| D68.9 | Coagulation defect, unspecified | Abnormal coagulation labs, etiology not yet determined |
| D69.1 | Qualitative platelet defects | Normal platelet count but abnormal function |
| D69.6 | Thrombocytopenia, unspecified | Low platelet count causing bleeding risk |
A quick coding pearl: D68.32 is the code you’ll reach for when a patient on warfarin presents with a supratherapeutic INR and bleeding. Don’t default to D68.9 when a more specific code applies.
What Actually Causes Coagulation Defects?
Coagulation defects split neatly into two camps: inherited and acquired. The distinction matters because it changes everything — from the urgency of workup to long-term management.
Inherited Coagulation Disorders
- Hemophilia A — Factor VIII deficiency, X-linked recessive, affects roughly 1 in 5,000 male births. Accounts for about 80% of all hemophilia cases.
- Hemophilia B — Factor IX deficiency, X-linked recessive, affects about 1 in 25,000 male births. Clinically indistinguishable from hemophilia A without factor assays.
- Von Willebrand disease (VWD) — The most common inherited bleeding disorder, affecting up to 1% of the population. Type 1 (partial quantitative deficiency) accounts for 70-80% of cases.
- Rare factor deficiencies — Factor XI deficiency is the most common of the “rare” deficiencies, particularly prevalent in the Ashkenazi Jewish population (up to 8% carrier rate).
Acquired Coagulation Disorders
- Liver disease — The liver synthesizes nearly all clotting factors. Cirrhosis can cause a complex coagulopathy with both bleeding and clotting risk.
- Vitamin K deficiency — Affects factors II, VII, IX, and X. Common in malnutrition, prolonged antibiotic use, and neonates.
- Disseminated intravascular coagulation (DIC) — Simultaneous widespread clotting and bleeding, triggered by sepsis, trauma, malignancy, or obstetric emergencies.
- Drug-induced — Warfarin, heparin, and direct oral anticoagulants (DOACs) are the most frequent culprits.
- Acquired factor inhibitors — Autoantibodies against factor VIII (acquired hemophilia A) carry a mortality rate of 8-22%, and the median age at diagnosis is around 75 years.
How Coagulation Defects Are Diagnosed
The diagnostic workup starts with two fundamental screening tests: prothrombin time (PT/INR) and activated partial thromboplastin time (aPTT). The pattern of abnormality points you toward the defect.
| PT/INR | aPTT | Most Likely Defects |
|---|---|---|
| Normal | Prolonged | Hemophilia A or B, factor XI or XII deficiency, VWD, heparin effect, lupus anticoagulant |
| Prolonged | Normal | Factor VII deficiency, early warfarin therapy, mild liver disease |
| Prolonged | Prolonged | DIC, severe liver disease, vitamin K deficiency, warfarin (therapeutic), common pathway defect (factors II, V, X, fibrinogen) |
| Normal | Normal | Factor XIII deficiency, mild VWD, platelet function disorders, vascular disorders |
After screening, mixing studies distinguish between factor deficiencies (the prolonged time corrects when patient plasma is mixed 1:1 with normal plasma) and inhibitors (the time does not correct). From there, specific factor assays quantify individual factor levels.
For suspected inherited disorders, genetic testing confirms the diagnosis and is essential for carrier detection and genetic counseling. Hemophilia severity is classified by factor level: severe (<1%), moderate (1-5%), and mild (5-40%).
Management and Treatment Strategies
Factor Replacement Therapy
The backbone of hemophilia management is replacing the missing clotting factor. Recombinant factor concentrates are preferred over plasma-derived products due to lower infectious risk. Extended half-life products now allow prophylactic dosing every 3-5 days for hemophilia A and every 7-14 days for hemophilia B, a significant quality-of-life improvement.
Non-Factor Therapies
Emicizumab (Hemlibra) has transformed hemophilia A management. This bispecific antibody mimics the function of factor VIII and is given subcutaneously, even working in patients with factor VIII inhibitors. Clinical trials showed a 87% reduction in treated bleeds compared to no prophylaxis.
Desmopressin (DDAVP)
For mild hemophilia A and type 1 VWD, DDAVP releases stored von Willebrand factor and factor VIII from endothelial cells. It’s a first-line option for minor bleeds and surgical prophylaxis in responsive patients. A trial dose with pre- and post-infusion factor levels should be documented before relying on it.
Managing Acquired Coagulopathies
- Vitamin K deficiency — IV or oral vitamin K; response within 12-24 hours.
- Warfarin reversal — 4-factor prothrombin complex concentrate (4F-PCC) for life-threatening bleeding; vitamin K for non-urgent correction.
- DIC — Treat the underlying cause. Supportive care with platelets, cryoprecipitate (fibrinogen <100 mg/dL), and fresh frozen plasma as needed.
- Acquired hemophilia A — Bypassing agents (aPCC or rFVIIa) to control acute bleeding, plus immunosuppression (typically steroids ± cyclophosphamide or rituximab) to eradicate the inhibitor.
When to See a Doctor
Seek medical evaluation if you experience any of the following:
- Unexplained bruising, especially large or in unusual locations (trunk, back)
- Prolonged bleeding after dental procedures, surgery, or minor cuts (>15-20 minutes)
- Recurrent nosebleeds lasting longer than 10 minutes despite pressure
- Heavy menstrual bleeding requiring pad/tampon changes every 1-2 hours
- Joint swelling, warmth, or stiffness without trauma — a hallmark of hemarthrosis
- Blood in urine or stool without an obvious cause
- A family history of bleeding disorders, especially if you’re planning surgery or pregnancy
If your routine labs show an unexpectedly prolonged PT or aPTT, ask your doctor whether a hematology referral and mixing study are warranted.
Frequently Asked Questions
What is the ICD 10 code for coagulation defect, unspecified?
The code is D68.9. It’s used when a patient has a documented coagulation abnormality but the specific defect hasn’t been identified. Ideally, this code should be a placeholder — once diagnostic workup is complete, a more specific code (like D66 for hemophilia A or D68.0 for VWD) should replace it.
What’s the difference between D68.4 and D68.32?
D68.4 covers acquired coagulation factor deficiency due to medical conditions like liver disease or vitamin K deficiency. D68.32 specifically captures hemorrhagic disorders caused by extrinsic circulating anticoagulants — meaning drug-induced coagulopathy from medications like warfarin, heparin, or DOACs. If a patient on warfarin is bleeding, D68.32 is the more accurate code.
Can you have a coagulation defect with normal PT and aPTT?
Yes. Factor XIII deficiency is the classic example — it causes severe bleeding (including umbilical stump bleeding in neonates and intracranial hemorrhage) but PT and aPTT are completely normal because factor XIII acts after the fibrin clot has already formed. Mild von Willebrand disease and platelet function disorders like Glanzmann thrombasthenia also present with normal standard coagulation tests.
How is hemophilia severity classified?
Severity is based on baseline clotting factor activity: severe is less than 1% of normal (<0.01 IU/mL), moderate is 1-5% (0.01-0.05 IU/mL), and mild is 5-40% (0.05-0.40 IU/mL). Patients with severe hemophilia typically experience spontaneous joint and muscle bleeds, while those with mild hemophilia may only bleed excessively after trauma or surgery.
Is von Willebrand disease the same as hemophilia?
No, though they can overlap. Von Willebrand disease is caused by a deficiency or dysfunction of von Willebrand factor (VWF), a protein that helps platelets stick to injured blood vessel walls and also carries factor VIII in the bloodstream. Because VWF stabilizes factor VIII, severe VWD can cause low factor VIII levels and mimic hemophilia A. However, VWD is autosomal (affects men and women equally), while hemophilia A and B are X-linked (predominantly affecting males).
